Literature DB >> 23079745

Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.

Jeong Kyu Kim1, Ji Heon Noh, Kwang Hwa Jung, Jung Woo Eun, Hyun Jin Bae, Min Gyu Kim, Young Gyoon Chang, Qingyu Shen, Won Sang Park, Jung Young Lee, Jürgen Borlak, Suk Woo Nam.   

Abstract

UNLABELLED: Sirtuins are nicotinamide adenine dinucleotide oxidized form (NAD(+) )-dependent deacetylases and function in cellular metabolism, stress resistance, and aging. For sirtuin7 (SIRT7), a role in ribosomal gene transcription is proposed, but its function in cancer has been unclear. In this study we show that SIRT7 expression was up-regulated in a large cohort of human hepatocellular carcinoma (HCC) patients. SIRT7 knockdown influenced the cell cycle and caused a significant increase of liver cancer cells to remain in the G1 /S phase and to suppress growth. This treatment restored p21(WAF1/Cip1) , induced Beclin-1, and repressed cyclin D1. In addition, sustained suppression of SIRT7 reduced the in vivo tumor growth rate in a mouse xenograft model. To explore mechanisms in SIRT7 regulation, microRNA (miRNA) profiling was carried out. This identified five significantly down-regulated miRNAs in HCC. Bioinformatics analysis of target sites and ectopic expression in HCC cells showed that miR-125a-5p and miR-125b suppressed SIRT7 and cyclin D1 expression and induced p21(WAF1/Cip1) -dependent G1 cell cycle arrest. Furthermore, treatment of HCC cells with 5-aza-2'-deoxycytidine or ectopic expression of wildtype but not mutated p53 restored miR-125a-5p and miR-125b expression and inhibited tumor cell growth, suggesting their regulation by promoter methylation and p53 activity. To show the clinical significance of these findings, mutations in the DNA binding domain of p53 and promoter methylation of miR-125b were investigated. Four out of nine patients with induced SIRT7 carried mutations in the p53 gene and one patient showed hypermethylation of the miR-125b promoter region.
CONCLUSION: Our findings suggest the oncogenic potential of SIRT7 in hepatocarcinogenesis. A regulatory loop is proposed whereby SIRT7 inhibits transcriptional activation of p21(WAF1/Cip1) by way of repression of miR-125a-5p and miR-125b. This makes SIRT7 a promising target in cancer therapy. (HEPATOLOGY 2013).
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23079745     DOI: 10.1002/hep.26101

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  141 in total

Review 1.  Epigenetics of hepatocellular carcinoma: role of microRNA.

Authors:  Sharad Khare; Qiong Zhang; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7.

Authors:  Jia Yu; Bo Qin; Fengying Wu; Sisi Qin; Somaira Nowsheen; Shan Shan; Jacqueline Zayas; Huadong Pei; Zhenkun Lou; Liewei Wang
Journal:  Cell Rep       Date:  2017-01-31       Impact factor: 9.423

Review 3.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

Review 4.  The nucleolus—guardian of cellular homeostasis and genome integrity.

Authors:  Ingrid Grummt
Journal:  Chromosoma       Date:  2013-12       Impact factor: 4.316

5.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  High expression of Sirt7 served as a predictor of adverse outcome in breast cancer.

Authors:  Qian Geng; Haoyu Peng; Fengsheng Chen; Rongcheng Luo; Rong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 7.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

8.  MiR-125b attenuates human hepatocellular carcinoma malignancy through targeting SIRT6.

Authors:  Shi Song; Yuxia Yang; Minghui Liu; Boya Liu; Xin Yang; Miao Yu; Hao Qi; Mengmeng Ren; Zhe Wang; Junhua Zou; Feng Li; Xiaojuan Du; Hongquan Zhang; Jianyuan Luo
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 9.  Regulation of SIRT1 by microRNAs.

Authors:  Sung-E Choi; Jongsook Kim Kemper
Journal:  Mol Cells       Date:  2013-11-06       Impact factor: 5.034

10.  Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2.

Authors:  Felice H Tsang; Victor Au; Wen-Jing Lu; Felix H Shek; Angela M Liu; John M Luk; Sheung-Tat Fan; Ronnie T P Poon; Nikki P Lee
Journal:  Dig Dis Sci       Date:  2014-05-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.